The mortality and response rate after FLANG regimen in patients with refractory/relapsed acute leukemia

BACKGROUND: Oncologists today are greatly concerned about the treatment of relapsed/refractory acute leukemia. FLANG regimen, combination of novantron, cytarabine, fludarabine, and granulocyte-colony stimulating factor, has been used in treatment of refractory/relapsed acute leukemia since 1990s. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehrzad, Vali A., Liaghat, Lida, Ashrafi, Farzaneh, Tazhibi, Mehdi, Hajalikhani, Mehri, Alijanian, Neda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544098/
https://www.ncbi.nlm.nih.gov/pubmed/23326785
http://dx.doi.org/10.4103/2277-9175.100166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544098/
https://www.ncbi.nlm.nih.gov/pubmed/23326785
http://dx.doi.org/10.4103/2277-9175.100166

Ejemplares similares